In a Kras-driven genetically engineered mouse model reflecting NSCLC biology and response to therapy (Jackson et al., 2001; Johnson et al., 2001; Singh et al., 2010), deletion of NF-κB severely impairs tumor growth (Meylan et al., 2009). This evidence concerns the gene KRAS and neoplasm.